Bladder Cancer Risk Stratification: Moving from the Old to the New
Joshua J. Meeks, MD, PhD, discusses risk stratification and treatment options for patients with non-muscle-invasive bladder cancer (NMIBC).
Read More
International Bladder Cancer Update
Alternative Payment Models: Value Care Bundling
Cary (C.J.) Stimson, MD, JD, discusses the potential of value care bundling to improve the healthcare landscape.
Read More
Controversies in NMIBC: Guidelines and Beyond
Sam S. Chang, MD, MBA, discusses NMIBC guidelines, best practices, and controversies related to risk-stratification, surveillance, and treatment strategies.
Read More
Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?
Peter Black, MD, FACS, FRCSC, discusses trimodal therapy (TMT) as a bladder-sparing option for some patients with muscle-invasive bladder cancer (MIBC).
Read More
The Contribution of SWOG to Bladder Cancer Clinical Trials
Seth P. Lerner, MD, provides a comprehensive history of Bacille Calmette-Guerin (BCG) and SWOG ’s innovation in bladder cancer over the past three decades.
Read More